WATERTOWN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 4, 2026 to report its fourth quarter and full-year 2025 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio ...

Joint U.S. Commercialization of RedHill's Talicia® Commences [Accessibility Statement] Skip NavigationThe full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings Inc. (THI), a jointly controlled entity of RedHill and Cumberland has started and is now being rolled out to support accelerated market penetration and expanded reachFocused on unlocking the full market potential of Talicia, the #1 branded U.S. gastroenterologist-prescribed H. pylori therap ...

NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines to treat brain disorders and symptoms caused by excess neural excitability, today announced that the Company’s management will participate in three upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference – Wednesday, February 25th at 11:20 am ET46th Annual TD Cowen Health Care Conference – Wednesday, March 4th at 9:50 am ETLeeri ...

Core Insights - Geron Corporation reported a net product revenue of $48 million for Q4 2025 and $184 million for the full year 2025, indicating a growth in demand for RYTELO [1][5] - The company ended 2025 with approximately $401 million in cash and marketable securities, down from $503 million in 2024 [4][22] - Geron reiterated its financial guidance for 2026, expecting RYTELO net product revenue between $220 million and $240 million, and total operating expenses between $230 million and $240 million [1][14] Financial Performance - Total product revenue for Q4 2025 was $48 million, compared to $47.5 million in Q4 2024, while full-year revenue increased from $76.5 million in 2024 to $183.6 million in 2025 [7][8] - The company reported a net loss of $31.1 million for Q4 2025, compared to a net loss of $25.4 million in Q4 2024, and a total net loss of $85.8 million for the full year 2025, down from $174.6 million in 2024 [5][6] - Total operating expenses for 2025 were $255 million, slightly above the previous year's $250.7 million [9] Operational Highlights - RYTELO demand grew by 9% in Q4 2025 compared to Q3 2025, with an increase of 150 ordering accounts, bringing the total to approximately 1,300 [5] - The company is focusing on driving U.S. commercial growth and exploring international opportunities for RYTELO, supported by FDA approval and scientific evidence [2][22] - Geron is preparing for the IMpactMF interim analysis in relapsed/refractory myelofibrosis and anticipates initial data from real-world experience trials in lower-risk MDS in the second half of 2026 [2] Cost Management - Research and development expenses decreased to $73.7 million in 2025 from $103.7 million in 2024, primarily due to lower clinical trial costs following RYTELO's approval [11] - Selling, general, and administrative expenses increased to $159.3 million in 2025 from $145.7 million in 2024, attributed to higher sales and marketing investments [12] - Restructuring charges of $17 million were incurred in 2025 due to a workforce reduction of approximately one-third of the staff [13]

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present at the TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026 at 10:30 a.m. ET. A live webcast of the event will be available in the Investors section of ...

FDA PDUFA Goal Date Set for October 17, 2026RESEARCH TRIANGLE PARK, N.C., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for phentolamine ophthalmic solution 0. ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Richard Pops, one of the biopharmaceutical industry’s longest-serving chief executives, will step down as the head of Alkermes at the end of July, the company announced Wednesday. Pops will be succeed by Chief Operating Officer Blair Jackson on July 31, Alkermes said. He’ll remain Alkermes’ board chair afterwards and help advise the company’s executive team. ...

Highlights (unaudited): Consistent Revenue Growth: Immuron is no longer just a "concept" company. Global H1 FY26 sales grew to AUD$4.2 million, with the U.S. market showing strong momentum (+17% YoY).Cash (AUD $10.0 million) to fund operating activities. Includes AUD $7.3 million (net) raised at an average price of A$0.0803 (IMRN USD$2.0923).Validated Platform: The "Hyper-Immune" platform is versatile. Beyond traveler’s diarrhea (Travelan®), the company is moving into high-value clinical targets like C. dif ...

GSK to buy 35Pharma for $950 million | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]GSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration [Purchase Licensing Rights, opens new tab]- Companies[GSK plc]FollowFeb 25 (Reuters) - GSK [(GSK.L), opens new tab] on Wednesday agreed to buy Canadian biopharmaceutical company 35Pharma Inc for $950 million in cash.Sign up [here.]Reporting by ...

Acquisition includes HS235, a potentially best-in-class activin signalling inhibitor in clinical development for treatment of cardiopulmonary diseasesHS235 offers potential to treat pulmonary hypertension (PH) patients while reducing the risk of bleeding and providing unique metabolic benefits compared to existing therapies MONTREAL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- 35Pharma, a Canada-based, private, clinical-stage biopharmaceutical company specialised in the development of novel protein-based therapeutics ...